It is considered that MetS patients with insulin resistance may have inhibition of tyrosine phosphorylation of IRS1, leading to downregulation of Akt2 phosphorylation; the suppression of Akt2 activation keeps FOXO1 in the nucleus, resulting in persistent or excessive activation of hepatic gluconeogenesis32. The gene discussed is AKT2; the disease is metabolic syndrome.